Efficacy of etanercept in the treatment of juvenile idiopathic arthritis;Efectividad del etanercept en el tratamiento de la artritis idiopática juvenil

Anales de Pediatria

Volumn 70, Issue 4, 2009, Pages 354-361

  De Inocencio Arocena, J ^a   Merino Munoz R ^a   Alvarez Madrid C ^a   Garcia Consuegra Molina J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

American College of Rheumatology Pediatric 30; Effective treatment; Etanercept; Juvenile Idiopathic Arthritis

Indexed keywords

ETANERCEPT;

ARTICLE; CHILD; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 64049110257     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2008.12.011     Document Type: Article

References (40)

1. B.A. Gäre, and A. Fasth Epidemiology of juvenile chronic arthritis in southwestern Sweden: A 5-year prospective population study Pediatrics 90 1992 950 958
2. Grupo Español de Reumatología Pediátrica Registro Nacional de Enfermedades Reumáticas Infantiles An Esp Pediatr 45 1996 346 350
3. R.E. Petty, T.R. Southwood, P. Manners, J. Baum, D.N. Glass, and J. Goldenberg International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001 J Rheumatol 31 2004 390 392
4. Merino R, De Inocencio J, García-Consuegra J. Evaluation of revised International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in Spanish children (Edmonton 2001). J Rheumatol. 2005;32:559-61.
5. G. Gartlehner, R.A. Hansen, B.L. Jonas, P. Thieda, and K.N. Lohr Biologics for the treatment of juvenile idiopathic arthritis: A systematic review and critical analysis of the evidence Clin Rheumatol 27 2008 67 76
6. J. García-Consuegra Molina, R. Merino Muñoz, and J. De Inocencio Arocena Artritis idiopática juvenil: tratamiento actual y perspectivas terapéuticas Rev Esp Reumatol 30 2003 338 347
7. D.J. Lovell, E.H. Giannini, A. Reiff, G.J. Cawkwell, E.D. Silverman, and J.J. Nocton Etanercept in children with polyarticular juvenile rheumatoid arthritis New Engl J Med 342 2000 763 769
8. N. Ruperto, D.J. Lovell, R. Cuttica, N. Wilkinson, P. Woop, and G. Espada A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis Arthritis Rheum 56 2007 3096 3106
9. D.J. Lovell, N. Ruperto, S. Goodman, A. Reiff, L. Jung, and K. Jarasova Adalimumab with or without methotrexate in juvenile rheumatoid arthritis N Engl J Med 359 2008 810 820
10. V. Pascual, F. Allantaz, E. Arce, M. Punaro, and J. Banchereau Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade J Exp Med 201 2005 1479 1486
11. S. Yokota, T. Imagawa, M. Mori, T. Miyamae, Y. Aihara, and S. Takei Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase iii trial Lancet 371 2008 998 1006
12. N. Ruperto, D.J. Lovell, P. Quartier, E. Paz, N. Rubio-Pérez, and C.A. Silva Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial Lancet 372 2008 383 391
13. Mulero Mendoza J, Vera Mendoza M. Infliximab y etanercept hoy. Inf Ter Sist Nac Salud 2003;27:168-74 [citado 12 Agosto 2008]. Disponible en: URL: http://www.msc.es/biblioPublic/publicaciones/docs/vol27-6infliximab.pdf.
14. E.H. Giannini, N. Ruperto, A. Ravelli, D.J. Lovell, D.T. Felson, and A. Martini Preliminary definition of improvement in juvenile arthritis Arthritis Rheum 40 1997 1202 1209
15. J. De Inocencio, J. García-Consuegra, R. Merino, I. Calvo, J.J. García, N. Ruperto for the Paediatric Rheumatology International Trials Organisation (PRINTO) The European Spanish version of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ) Clin Exp Rheumatol 19 Suppl. 23 2001 S141 S145
16. A. Lurati, I. Pontikaki, B. Teruzzi, F. Desiati, V. Gerloni, and M. Gattinara A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor α agents Arthritis Rheum 54 2006 1602 1607
17. G. Horneff, H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, and H.J. Girschick The German etanercept registry for treatment of juvenile idiopathic arthritis Ann Rheum Dis 63 2004 1638 1644
18. P. Quartier, P. Taupin, F. Bourdeaut, I. Lemelle, P. Pillet, and M. Bost Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type Arthritis Rheum 48 2003 1093 1101
19. I. Calvo Penadés, B. López Montesinos, R. Merino, J. García-Consuegra, P. Moreno Pascual, and B. Bravo Tratamiento con etanercept en la artritis idiopática juvenil (AIJ): resultados de un registro retrospectivo multicéntrico español An Pediatr (Barc) 64 supl 3 2006 252
20. Y. Kimura, P. Pinho, G. Walco, G. Higgins, D. Hummell, and I. Szer Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis J Rheumatol 32 2005 935 942
21. B.A. Eberhard, and N.T. Ilowite Response of systemic onset juvenile rheumatoid arthritis to etanercept: Is the glass half full or half empty? J Rheumatol 32 2005 763 765
22. J. Braun, N. McHugh, A. Singh, J.S. Wajdula, and R. Sato Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly Rheumatology 46 2007 999 1004
23. M. Henrickson, and A. Reiff Prolonged efficacy of etanercept in refractory enthesitis-related arthritis J Rheumatol 31 2004 2055 2061
24. S.M.L. Tse, R. Burgos-Vargas, and R.M. Laxer Anti-tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathy Arthritis Rheum 52 2005 2103 2108
25. R.K. Saurenmann, A.V. Levin, B.M. Feldman, R.M. Laxer, R. Schneider, and E.D. Silverman Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agents J Pediatr 149 2006 833 836
26. H. Schmeling, and G. Horneff Etanercept and uveitis in patients with juvenile idiopathic arthritis Rheumatology 44 2005 1008 1011
27. J.A. Smith, D.J. Thompson, S.M. Whitcup, E. Suhler, G. Clarke, and S. Smith A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 53 2005 18 23
28. C.E. Rabinovich Use of tumor necrosis factor inhibitors in uveitis Curr Opin Rheumatol 19 2007 482 486
29. F.R. Imrie, and A.D. Dick Biologics in the treatment of uveitis Curr Opin Ophthalmol 18 2007 481 486
30. J.J. Gómez-Reino, L. Carmona, V.R. Valverde, E.M. Mola, M.D. Montero BIOBADASER Group Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report Arthritis Rheum 48 2003 2122 2127
31. M.D. Magnano, W.H. Robinson, and M.C. Genovese Demyelination and inhibition of tumor necrosis factor (TNF) Clin Exp Rheumatol 22 Supl 35 2004 S134 S140
32. J.P. Stübgen Tumor necrosis factor-α antagonists and neuropathy Muscle Nerve 37 2008 281 292
33. T. Tauber, D. Daniel, J. Barash, J. Turetz, and Y. Morad Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis Rheumatology 44 2005 405
34. J. García-Consuegra Molina, R. Merino Muñoz, J. De Inocencio Arocena grupo de estudio del síndrome de activación macrofágica y artritis idiopática juvenil, de la Sociedad Española de Reumatología Pediátrica Síndrome de activación macrofágica y artritis idiopática juvenil. Resultados de un estudio multicéntrico An Pediatr (Barc) 68 2008 110 116
35. S. Prahalad, K.E. Bove, D. Dickens, D.J. Lovell, and A.A. Grom Etanercept in the treatment of macrophage activation syndrome J Rheumatol 28 2001 2120 2124
36. B. Makay, S. Yilmaz, Z. Türkyilmaz, N. Unal, H. Oren, and E. Unsal Etanercept for therapy-resistant macrophage activation syndrome Pediatr Blood Cancer 50 2008 419 421
37. V. Gerloni, I. Pontikaki, M. Gattinara, and F. Fantini Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients Ann Rheum Dis 67 2008 1145 1152
38. D.J. Lovell, A. Reiff, O.Y. Jones, R. Schneider, J. Nocton, and L.D. Stein Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis Arthritis Rheum 54 2006 1987 1994
39. D.J. Lovell, A. Reiff, N.T. Ilowite, C.A. Wallace, Y. Chon, and S.L. Lin Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Arthritis Rheum 58 2008 1496 1504
40. F. Kanakoudi-Tsakalidou, V. Tzimouli, P. Pratsidou-Gertsi, E. Chronopoulou, and M. Trachana The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment Cytokine 42 2008 293 297